Widespread implementation of prophylactic human papillomavirus (HPV) vaccines, one of which recently has become available for clinical use, could substantially decrease morbidity and mortality from cervical cancer and other HPV-related diseases. However, little is known about two factors fundamentally important to maximizing the health impact of vaccination: whether vaccination will change perceptions of risk, which may in turn impact sexual behaviors and risk for sexually transmitted infections (STI), and whether widespread virus-type-specific vaccination will affect the subsequent distribution of non-vaccine types in the population. The overall objectives of this application are to examine the impact of HPV vaccination on adolescent attitudes, sexual behaviors, STI acquisition, and HPV type distribution. The central hypotheses are that adolescent perceptions of reduced risk immediately post-vaccination will be associated subsequently with an increase in risky sexual behaviors and STI rates, and that widespread vaccination will shift the population distribution of HPV over time to non-vaccine genotypes. Guided by our preliminary data, this hypothesis will be tested by pursuing the following three specific aims: 1) Determine whether 13-17 year-old female adolescents'attitudes (e.g. risk perceptions) change as a result of HPV vaccination, whether parent and provider factors influence adolescent risk perceptions post-vaccination, and whether these risk perceptions predict subsequent sexual behaviors and STI diagnosis;2) Explore qualitatively 11-12 year-old girls'knowledge and attitudes (e.g. risk perceptions) after HPV vaccination, whether parent and provider factors influence girls'knowledge and risk perceptions, and whether these risk perceptions influence subsequent sexual behaviors;and 3) Determine overall and type- specific HPV prevalence in a diverse sample of sexually active adolescent and young adult women, before and after widespread HPV vaccine implementation. In order to achieve the study objectives we will use the following approach. The first two aims will be addressed using longitudinal cohort studies of 11-12 year-old and 13-17 year-old girls, their mothers and their providers.
The third aim will be addressed using two cross- sectional surveillance studies, before and after widespread HPV vaccination, in a diverse sample of sexually active young women. The approach is innovative, because the investigators are taking a multidisciplinary approach to understanding a previously unexplored area: the attitudinal, behavioral, and virologic impact of HPV vaccination in young women. The proposed research is significant, because the results are expected to help direct the development of evidence-based educational interventions designed to promote safe sexual behaviors after vaccination;contribute to the development of future multivalent vaccines;guide the design of post-vaccination surveillance studies of HPV epidemiology and vaccine efficacy;and create educational interventions and Pap screening recommendations that take into account shifts in viral type after vaccination. Relevance to Public Health: Examination of the attitudinal, behavioral, and virologic impact of type-specific HPV vaccination is an important but under-investigated area of behavioral science and virology that has direct implications for maximizing the public health impact of HPV vaccines. The results are expected to guide the development of evidence-based educational interventions and future multivalent HPV vaccines, both of which could maximize the effectiveness of vaccination in preventing HPV-related diseases such as cervical cancer. This application addresses several objectives of Healthy People 2010, including reducing the proportion of persons with HPV infection (objective 25-5) and reducing the death rate from cervical cancer (objective 3-4).

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project (R01)
Project #
5R01AI073713-05
Application #
8204950
Study Section
Infectious Diseases, Reproductive Health, Asthma and Pulmonary Conditions Study Section (IRAP)
Program Officer
David, Hagit S
Project Start
2008-01-15
Project End
2013-06-30
Budget Start
2012-01-01
Budget End
2013-06-30
Support Year
5
Fiscal Year
2012
Total Cost
$501,511
Indirect Cost
$143,683
Name
Cincinnati Children's Hospital Medical Center
Department
Type
DUNS #
071284913
City
Cincinnati
State
OH
Country
United States
Zip Code
45229
Mesher, David; Soldan, Kate; Lehtinen, Matti et al. (2016) Population-Level Effects of Human Papillomavirus Vaccination Programs on Infections with Nonvaccine Genotypes. Emerg Infect Dis 22:1732-40
Whittemore, Dana; Ding, Lili; Widdice, Lea E et al. (2016) Distribution of Vaccine-Type Human Papillomavirus Does Not Differ by Race or Ethnicity Among Unvaccinated Young Women. J Womens Health (Larchmt) 25:1153-1158
Kahn, Jessica A; Widdice, Lea E; Ding, Lili et al. (2016) Substantial Decline in Vaccine-Type Human Papillomavirus (HPV) Among Vaccinated Young Women During the First 8 Years After HPV Vaccine Introduction in a Community. Clin Infect Dis 63:1281-1287
Mullins, Tanya L Kowalczyk; Zimet, Gregory D; Rosenthal, Susan L et al. (2016) Human papillomavirus vaccine-related risk perceptions and subsequent sexual behaviors and sexually transmitted infections among vaccinated adolescent women. Vaccine 34:4040-5
Drolet, Mélanie; Bénard, Élodie; Boily, Marie-Claude et al. (2015) Population-level impact and herd effects following human papillomavirus vaccination programmes: a systematic review and meta-analysis. Lancet Infect Dis 15:565-80
Mullins, Tanya L Kowalczyk; Widdice, Lea E; Rosenthal, Susan L et al. (2015) Risk perceptions, sexual attitudes, and sexual behavior after HPV vaccination in 11-12 year-old girls. Vaccine 33:3907-12
Mayhew, Allison; Mullins, Tanya L Kowalczyk; Ding, Lili et al. (2014) Risk perceptions and subsequent sexual behaviors after HPV vaccination in adolescents. Pediatrics 133:404-11
Mullins, Tanya L Kowalczyk; Griffioen, Anne M; Glynn, Susan et al. (2013) Human papillomavirus vaccine communication: perspectives of 11-12 year-old girls, mothers, and clinicians. Vaccine 31:4894-901
Griffioen, Anne M; Glynn, Susan; Mullins, Tanya K et al. (2012) Perspectives on decision making about human papillomavirus vaccination among 11- to 12-year-old girls and their mothers. Clin Pediatr (Phila) 51:560-8
Widdice, Lea E; Brown, Darron R; Bernstein, David I et al. (2012) Prevalence of human papillomavirus infection in young women receiving the first quadrivalent vaccine dose. Arch Pediatr Adolesc Med 166:774-6

Showing the most recent 10 out of 13 publications